Market cap
$4,621 Mln
Recently Viewed
Clear AllMarket cap
$4,621 Mln
Revenue (TTM)
$235 Mln
P/E Ratio
--
P/B Ratio
39
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-322 Mln
ROE
-1.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-16.5
Debt to Equity
4.9
Book Value
$--
EPS
$-5
Face value
--
Shares outstanding
67,476,200
CFO
$-1,024.92 Mln
EBITDA
$-1,220.39 Mln
Net Profit
$-1,276.38 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Global Blood Therapeutics (GBT)
| 134.0 | 1.0 | 108.8 | 162.2 | 12.5 | 16.2 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|
|
Global Blood Therapeutics (GBT)
| -32.4 | -45.5 | 93.6 | 4.3 | 172.3 | -55.3 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Global Blood Therapeutics (GBT)
|
68.5 | 4,621.4 | 234.9 | -322.5 | -126.6 | -204.9 | -- | 39.0 |
| 27.5 | 9,025.2 | 3,497.4 | -77.0 | 4.3 | -2.4 | -- | 2.7 | |
| 18.7 | 732.4 | 1,175.5 | 37.3 | 5.8 | 31.7 | 19.7 | 5.8 |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral,... once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California. Read more
Pres, CEO & Director
Dr. Ted W. Love M.D.
Pres, CEO & Director
Dr. Ted W. Love M.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Global Blood Therapeutics Inc (GBT) is $68.49 (NASDAQ) as of 05-Oct-2022 09:30 EDT. Global Blood Therapeutics Inc (GBT) has given a return of 12.53% in the last 3 years.
Since, TTM earnings of Global Blood Therapeutics Inc (GBT) is negative, P/E ratio is not available.
The P/B ratio of Global Blood Therapeutics Inc (GBT) is 39.05 times as on 05-Oct-2022, a 584 premium to its peers’ median range of 5.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-6.08
|
9.39
|
|
2020
|
-10.67
|
6.35
|
|
2019
|
-17.28
|
7.97
|
|
2018
|
-12.02
|
3.65
|
|
2017
|
-14.12
|
5.18
|
The 52-week high and low of Global Blood Therapeutics Inc (GBT) are Rs -- and Rs -- as of 23-Apr-2026.
Global Blood Therapeutics Inc (GBT) has a market capitalisation of $ 4,621 Mln as on 05-Oct-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Global Blood Therapeutics Inc (GBT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.